The Latest Cardiac and Vascular News
Data also finds using materials that mimic the body’s chemistry leads to meaningful reductions in complications such as phlebitis, occlusion, and infections BILLERICA, Mass., July 12, 2022 (GLOBE NEWSWIRE) — Access Vascular, Inc. (AVI) today shared initial findings from a retrospective review of patient records that demonstrates an increase in dwell times […]
MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on improving the quality of life for people with fluid overload, today announced key takeaways from its recent physician-led webinar discussing the benefits of treating fluid overloaded heart failure (HF) patients with Aquadex® ultrafiltration (UF) in the […]
Study results favor FUROSCIX® versus “treatment as usual” in composite primary endpoint and all secondary endpoints FUROSCIX demonstrated an acceptable tolerability profile Company on track for Q4 2022 commercial launch of FUROSCIX, if approved BURLINGTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on […]
First and only machine learning algorithm to assist healthcare professionals in identifying structural heart murmurs using a smart stethoscope OAKLAND, Calif., July 12, 2022 /PRNewswire/ — Eko, a digital health company advancing heart and lung disease detection, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Eko Murmur Analysis […]
The new Barostim Programmer launches in the U.S., making Barostim therapy programming simpler and enabling remote view access to enhance customer support MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched […]
Phase 1b Clinical Trial, heart-1, Now Underway and Enrolling Patients with Heterozygous Familial Hypercholesterolemia in New Zealand Company Executing VERVE-101 Global Regulatory Strategy with Potential Clearances for a UK Clinical Trial Application and US Investigational New Drug Application in Second Half of 2022 CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) […]
NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-L, its allogeneic “off-the-shelf” product candidate for the treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF), will be highlighted in a panel discussion […]
Renowned Cardiologist and Innovator Brings Unparalleled Expertise to Story Health and Fuels Mission of Transforming Care for Americans with Heart Failure SAN JOSE, Calif.–(BUSINESS WIRE)–Story Health, a health technology and services company that extends specialty care to patients’ homes, today announced the appointment of Dr. Andrew Sauer to its Board […]
IRVINE, Calif.–(BUSINESS WIRE)–Vascular Dynamics, Inc. (VDI), a privately held medical device company focused on developing game-changing endovascular device-based solutions for patients suffering from heart failure, has announced the closing of its $20 million financing round led by an investment partner of VDI shareholder Rainbow Medical. Lawrence C. Best also joined existing […]
Fiscal Year 2022 Fourth Quarter Highlights Net sales of $87.0 million increased 13.2% compared to the prior-year quarter Gross margin of 53.4% declined 170 basis points year over year GAAP loss per share of $0.16 and adjusted earnings per share of $0.01 Cash and cash equivalents at May 31, 2022 […]
